Patient Preference and Adherence (Mar 2025)

Clinical Practice Evidence of Treatment Satisfaction with Moderate and High-Efficacy Drugs in Multiple Sclerosis

  • Barrero Hernández FJ,
  • Morales Lahoz ÁJ,
  • Serrano Gutiérrez C,
  • López Fandila E,
  • Asenjo Martín C,
  • González Ramírez MD,
  • Piñar-Morales R

Journal volume & issue
Vol. Volume 19
pp. 715 – 727

Abstract

Read online

Francisco Javier Barrero Hernández,1– 3 Ángel José Morales Lahoz,1 Cristina Serrano Gutiérrez,1 Elena López Fandila,1 Carolina Asenjo Martín,1 Maria Dolores González Ramírez,2 Raquel Piñar-Morales1– 3 1Department of Neurology, Hospital Clinico Universitario San Cecilio, Granada, Spain; 2Department of Medicine, Faculty of Medicine. University of Granada, Granada, Spain; 3Institute of Biosanitary Research: (IBS.Granada), Granada, SpainCorrespondence: Francisco Javier Barrero Hernández, Email [email protected]: Generally, the choice of disease-modifying treatment (DMT) for people with multiple sclerosis (PwMS) is based on aspects of efficacy and safety. However, due to the diversity of drugs and the different routes of administration, it is essential to know the experience and satisfaction of PwMS. Patient- reported outcomes (PROs) help us to optimize and improve adherence.Methods: Our objective with this cross-sectional, non-interventional study is to analyze satisfaction outcomes using the treatment satisfaction questionnaire for medication (TSQM) according to moderate or high efficacy of DMTs and the relationship with demographic, clinical and quality of life (QoL) aspects.Results: PwMS receiving high-efficacy DMTs show greater overall satisfaction, but not in the other TSQM subscales. The route of administration did not show differences in treatment satisfaction. The best QoL scores were observed in patients treated with oral DMTs compared to injectables or infusions.Discussion: The efficacy of DMT is a significant predictor of overall satisfaction. Quality of life has a minimal impact on overall satisfaction. EDSS, treatment duration and fatigue (MFIS) were not significant predictors of satisfaction outcomes. The knowledge provided by the PROs allows healthcare professionals to better understand the preferences and needs of PwMS, adjusting therapeutic strategies, improving patient experience and treatment effectiveness.Keywords: quality of life, relapsing remitting multiple sclerosis, fatigue, patient- reported outcomes, treatment satisfaction, disease-modifying treatment

Keywords